Urology
Expert Perspectives
Personalizing Kidney Stone Treatment to Prevent Recurrence
With a prevention-first approach, Dr. Esteban Emiliani Sanz sees kidney stones as a window into patient health.
NYU Langone Health: A Leader in Urology
Ranked #2 (tied)
in Urology
Top 5
in NIH funding (Source: Blue Ridge)
Pioneers in MRI
to evaluate prostate cancer
Complex Case Spotlight
Targeted Salvage Cryoablation Resolves Radio-Recurrent Prostate Cancer
Advanced Imaging Localizes Lesion & Rules Out Metastatic Disease
About 11 years after a diagnosis of prostate cancer treated with radiation therapy, a patient presented with progressively rising PSA levels. Multiparametric MRI revealed a lesion in the left medial posterior base peripheral zone; a subsequent MRI-ultrasound fusion biopsy demonstrated prostate cancer in 1 of 12 systematic cores and 3 of 3 targeted cores obtained from the lesion. An 18F-fluciclovine whole-body PET CT supported the conclusion of a local recurrence and found no evidence of metastatic disease.
Prostate imaging. A) Axial T2 MRI scan showing PI-RADS 5 lesion. B) Apparent diffusion coefficient map with corresponding region of restricted diffusion. C) 18F-fluciclovine PET demonstrating uptake in the left posterior prostate.
1 of 3
Salvage Cryoablation Treats Prostate Cancer Recurrence
Salvage partial gland cryoablation deploys the energy in a smaller and more focal treatment volume and at a slower rate to minimize the higher risk for side effects in a post-radiation setting. For the procedure, six V-probes were placed into the left posterior hemi-prostate, with six thermocouple probes at treatment boundaries to provide intraoperative temperature assessment of the margins.
Post-ablation imaging. A) Pretreatment MRI. B) Four-year post-ablation MRI showing no evidence of tumor.
2 of 3
Post-Treatment PSA Monitoring Affirms Successful Cancer Therapy
To be successful, salvage focal cryoablation requires careful patient selection and a meticulous treatment application; in addition, monitoring patients with serial PSA and MRI can provide essential clinical endpoints. Four years after the salvage cryoablation procedure, regular PSA monitoring has found no evidence of prostate cancer in the patient.
The patient’s PSA levels.
3 of 3
